Citations (48)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Lanfang Meng, Mengjun Shu, Yaqing Chen, Dexiao Yang, Qun He, Hui Zhao, Zhiyong Feng, Chris Liang & Ker Yu. (2014) A novel lead compound CM-118. Cancer Biology & Therapy 15:6, pages 721-734.
Read now
Read now
David Shahbazian, Armen Parsyan, Emmanuel Petroulakis, Ivan Topisirovic, Yvan Martineau, Bernard F. Gibbs, Yuri Svitkin & Nahum Sonenberg. (2010) Control of Cell Survival and Proliferation by Mammalian Eukaryotic Initiation Factor 4B. Molecular and Cellular Biology 30:6, pages 1478-1485.
Read now
Read now
Articles from other publishers (46)
Nimish Mol Stephen, Udayawara Rudresh Deepika, Tehreem Maradagi, Tatsuya Sugawara, Takashi Hirata & Ponesakki Ganesan. (2023) Insight on the cellular and molecular basis of blood vessel formation: A specific focus on tumor targets and therapy. MedComm – Oncology 2:1.
Crossref
Crossref
Evelina Folkesson, B. Cristoffer Sakshaug, Andrea D. Hoel, Geir Klinkenberg & Åsmund Flobak. (2023) Synergistic effects of complex drug combinations in colorectal cancer cells predicted by logical modelling. Frontiers in Systems Biology 3.
Crossref
Crossref
Velina S. Atanasova, Angelika Riedl, Marcus Strobl, Julia Flandorfer, Daniela Unterleuthner, Claudia Weindorfer, Patrick Neuhold, Simone Stang, Markus Hengstschläger, Michael Bergmann & Helmut Dolznig. (2023) Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition. International Journal of Molecular Sciences 24:2, pages 1668.
Crossref
Crossref
Smriti Chawla, Anja Rockstroh, Melanie Lehman, Ellca Ratther, Atishay Jain, Anuneet Anand, Apoorva Gupta, Namrata Bhattacharya, Sarita Poonia, Priyadarshini Rai, Nirjhar Das, Angshul Majumdar, Jayadeva, Gaurav Ahuja, Brett G. Hollier, Colleen C. Nelson & Debarka Sengupta. (2022) Gene expression based inference of cancer drug sensitivity. Nature Communications 13:1.
Crossref
Crossref
Meng-Hua Chen, Yue-Yu Gu, Anthony Lin Zhang, Daniel Man-yuen Sze, Sui-Lin Mo & Brian H. May. (2021) Biological effects and mechanisms of matrine and other constituents of Sophora flavescens in colorectal cancer. Pharmacological Research 171, pages 105778.
Crossref
Crossref
Elvire Pons-Tostivint, Benoît Thibault & Julie Guillermet-Guibert. (2017) Targeting PI3K Signaling in Combination Cancer Therapy. Trends in Cancer 3:6, pages 454-469.
Crossref
Crossref
Carl E. Allen, Theodore W. Laetsch, Rajen Mody, Meredith S. Irwin, Megan S. Lim, Peter C. Adamson, Nita L. Seibel, D. Williams Parsons, Y. Jae Cho & Katherine Janeway. (2017) Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial. JNCI: Journal of the National Cancer Institute 109:5.
Crossref
Crossref
Yueh-Hsiung Kuo, En-Pei Isabel Chiang, Che-Yi Chao, Raymond L. Rodriguez, Pei-Yu Chou, Shu-Yao Tsai, Man-Hui Pai & Feng-Yao Tang. (2017) Dual Inhibition of Key Proliferation Signaling Pathways in Triple-Negative Breast Cancer Cells by a Novel Derivative of Taiwanin A. Molecular Cancer Therapeutics 16:3, pages 480-493.
Crossref
Crossref
Emma J. Haagensen, Huw D. Thomas, Wolfgang A. Schmalix, Andrew C. Payne, Lara Kevorkian, Rodger A. Allen, Paul Bevan, Ross J. Maxwell & David R. Newell. (2016) Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037. Cancer Chemotherapy and Pharmacology 78:6, pages 1269-1281.
Crossref
Crossref
Hong Jun Kim, Suk-young Lee & Sang Cheul Oh. (2016) The Inositide Signaling Pathway As a Target for Treating Gastric Cancer and Colorectal Cancer. Frontiers in Physiology 7.
Crossref
Crossref
Rabih Said & Apostolia-Maria Tsimberidou. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
361
370
.
Jordi Rodon, Analia Azaro, Davis Torrejon & Razelle Kurzrock. 2015. Targeted Therapy in Translational Cancer Research. Targeted Therapy in Translational Cancer Research
14
26
.
Sally Temraz, Deborah Mukherji & Ali Shamseddine. (2015) Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers. International Journal of Molecular Sciences 16:9, pages 22976-22988.
Crossref
Crossref
Dionysios Papadatos-Pastos, Roy Rabbie, Paul Ross & Debashis Sarker. (2015) The role of the PI3K pathway in colorectal cancer. Critical Reviews in Oncology/Hematology 94:1, pages 18-30.
Crossref
Crossref
Judith S. Sebolt-Leopold. 2015. Targeted Therapy of Acute Myeloid Leukemia. Targeted Therapy of Acute Myeloid Leukemia
307
324
.
Marzieh Badinloo & Saeed Esmaeili-Mahani. (2014) Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines. Fundamental & Clinical Pharmacology 28:4, pages 414-422.
Crossref
Crossref
Jatin Roper, Mark J. Sinnamon, Erin M. Coffee, Peter Belmont, Lily Keung, Larissa Georgeon-Richard, Wei Vivian Wang, Anthony C. Faber, Jihye Yun, Ömer H. Yilmaz, Roderick T. Bronson, Eric S. Martin, Philip N. Tsichlis & Kenneth E. Hung. (2014) Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Letters 347:2, pages 204-211.
Crossref
Crossref
Haruhisa KitanoJoon-Yong ChungKris YlayaCatherine ConwayMikiko TakikitaJunya FukuokaYoshinori DokiJun HanaokaStephen M. Hewitt. (2014) Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer. Journal of Histochemistry & Cytochemistry 62:5, pages 335-346.
Crossref
Crossref
Feifei Li, Changqi Zhao & Lili Wang. (2014) Molecular-targeted agents combination therapy for cancer: Developments and potentials. International Journal of Cancer 134:6, pages 1257-1269.
Crossref
Crossref
MEI HONG ZHANG, HONG TAO MAN, XIAO DAN ZHAO, NI DONG & SHI LIANG MA. (2014) Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomedical Reports 2:1, pages 41-52.
Crossref
Crossref
Areumnuri Kim, Jung‐Eun Lee, Seung‐Sook Lee, Cherin Kim, Sun‐Joo Lee, Won‐Suk Jang & Sunhoo Park. (2013)
Coexistent mutations of
KRAS
and
PIK3CA
affect the efficacy of NVP‐BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
. International Journal of Cancer 133:4, pages 984-996.
Crossref
Crossref
Pedro Pablo González-Pérez & Maura Cárdenas-García. (2013) Modeling and Simulation of Molecular Mechanism of Action of Dietary Polyphenols on the Inhibition of Anti-Apoptotic PI3K/AKT Pathway. Computational Molecular Bioscience 03:03, pages 39-52.
Crossref
Crossref
Torsten Steinbrunn, Thorsten Stühmer, Cyrus Sayehli, Manik Chatterjee, Hermann Einsele & Ralf C. Bargou. (2012)
Combined targeting of
MEK
/
MAPK
and
PI
3
K
/
A
kt signalling in multiple myeloma
. British Journal of Haematology 159:4, pages 430-440.
Crossref
Crossref
Joseph D. Valentino, Victoria A. Elliott, Yekaterina Y. Zaytseva, Piotr G. Rychahou, W. Conan Mustain, Chi Wang, Tianyan Gao & B. Mark Evers. (2012) Novel small interfering RNA cotargeting strategy as treatment for colorectal cancer. Surgery 152:2, pages 277-285.
Crossref
Crossref
Joaquin MateoMichael OngTimothy A. YapJohann S. de Bono. (2012) Opportunities and Pitfalls of Targeted Therapeutic Combinations in Solid Tumors. American Society of Clinical Oncology Educational Book:32, pages 670-674.
Crossref
Crossref
Siker Kimbung, Ewa Biskup, Ida Johansson, Kristina Aaltonen, Astrid Ottosson-Wadlund, Sofia Gruvberger-Saal, Heather Cunliffe, Bengt Fadeel, Niklas Loman, Pontus Berglund & Ingrid Hedenfalk. (2012) Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibition. Cancer Letters 319:2, pages 232-241.
Crossref
Crossref
Ninel Azoitei, Christopher M. Hoffmann, Jana M. Ellegast, Claudia R. Ball, Kerstin Obermayer, Ulrike Gößele, Britta Koch, Katrin Faber, Felicitas Genze, Mark Schrader, Hans A. Kestler, Hartmut Döhner, Gabriela Chiosis, Hanno Glimm, Stefan Fröhling & Claudia Scholl. (2012) Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. Journal of Experimental Medicine 209:4, pages 697-711.
Crossref
Crossref
E J Haagensen, S Kyle, G S Beale, R J Maxwell & D R Newell. (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. British Journal of Cancer 106:8, pages 1386-1394.
Crossref
Crossref
Guilherme Z. Rocha, Marília M. Dias, Eduardo R. Ropelle, Felipe Osório-Costa, Franco A. Rossato, Anibal E. Vercesi, Mario J.A. Saad & José B.C. Carvalheira. (2011) Metformin Amplifies Chemotherapy-Induced AMPK Activation and Antitumoral Growth. Clinical Cancer Research 17:12, pages 3993-4005.
Crossref
Crossref
Jeremiah N. Winter, Leonard S. Jefferson & Scot R. Kimball. (2011) ERK and Akt signaling pathways function through parallel mechanisms to promote mTORC1 signaling. American Journal of Physiology-Cell Physiology 300:5, pages C1172-C1180.
Crossref
Crossref
Ensar Halilovic, Qing-Bai She, Qing Ye, Raymond Pagliarini, William R. Sellers, David B. Solit & Neal Rosen. (2010) PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling. Cancer Research 70:17, pages 6804-6814.
Crossref
Crossref
Arvind Dasari & Wells A. Messersmith. (2010) New Strategies in Colorectal Cancer: Biomarkers of Response to Epidermal Growth Factor Receptor Monoclonal Antibodies and Potential Therapeutic Targets in Phosphoinositide 3-Kinase and Mitogen-Activated Protein Kinase Pathways. Clinical Cancer Research 16:15, pages 3811-3818.
Crossref
Crossref
Hiroshi Hirai, Hiroshi Sootome, Yoko Nakatsuru, Katsuyoshi Miyama, Shunsuke Taguchi, Kyoko Tsujioka, Yoko Ueno, Harold Hatch, Pradip K. Majumder, Bo-Sheng Pan & Hidehito Kotani. (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs
In vitro
and
In vivo
. Molecular Cancer Therapeutics 9:7, pages 1956-1967.
Crossref
Crossref
Qing-Bai She, Ensar Halilovic, Qing Ye, Wei Zhen, Senji Shirasawa, Takehiko Sasazuki, David B. Solit & Neal Rosen. (2010) 4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors. Cancer Cell 18:1, pages 39-51.
Crossref
Crossref
Lucy Gossage & Tim Eisen. (2010) Targeting Multiple Kinase Pathways: A Change In Paradigm. Clinical Cancer Research 16:7, pages 1973-1978.
Crossref
Crossref
Nathan T. Ihle & Garth Powis. (2010) Inhibitors of phosphatidylinositol-3-kinase in cancer therapy. Molecular Aspects of Medicine 31:2, pages 135-144.
Crossref
Crossref
Pierre Mordant, Yohann Loriot, Céline Leteur, Julien Calderaro, Jean Bourhis, Marie Wislez, Jean-Charles Soria & Eric Deutsch. (2010) Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination. Molecular Cancer Therapeutics 9:2, pages 358-368.
Crossref
Crossref
Robert T. Abraham, James J. Gibbons & Edmund I. Graziani. 2010.
329
366
.
James J. Gibbons, Robert T. Abraham & Ker Yu. (2009) Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth. Seminars in Oncology 36, pages S3-S17.
Crossref
Crossref
Debashis Sarker, Alison H.M. Reid, Timothy A. Yap & Johann S. de Bono. (2009) Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. Clinical Cancer Research 15:15, pages 4799-4805.
Crossref
Crossref
Cristina P.R. Xavier, Cristovao F. Lima, Ana Preto, Raquel Seruca, Manuel Fernandes-Ferreira & Cristina Pereira-Wilson. (2009) Luteolin, quercetin and ursolic acid are potent inhibitors of proliferation and inducers of apoptosis in both KRAS and BRAF mutated human colorectal cancer cells. Cancer Letters 281:2, pages 162-170.
Crossref
Crossref
Susan Wee, Zainab Jagani, Kay Xiaoqin Xiang, Alice Loo, Marion Dorsch, Yung-Mae Yao, William R. Sellers, Christoph Lengauer & Frank Stegmeier. (2009) PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers. Cancer Research 69:10, pages 4286-4293.
Crossref
Crossref
Gary R. Hudes. (2009) Targeting mTOR in renal cell carcinoma. Cancer 115:S10, pages 2313-2320.
Crossref
Crossref
Mandira Ray & Gini Fleming. (2009) Management of Advanced-Stage and Recurrent Endometrial Cancer. Seminars in Oncology 36:2, pages 145-154.
Crossref
Crossref
Nathan T. Ihle & Garth Powis. (2009) Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy. Molecular Cancer Therapeutics 8:1, pages 1-9.
Crossref
Crossref
K Kojima, M Shimanuki, M Shikami, I J Samudio, V Ruvolo, P Corn, N Hanaoka, M Konopleva, M Andreeff & H Nakakuma. (2008) The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. Leukemia 22:9, pages 1728-1736.
Crossref
Crossref